Physician profile
Jesse Samuel
NPI 1902120934
$7,079.22
in general payments reported to CMS, 2019-2025
43 companies · $951 in 2025
The $951 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $818 · 2021: $799 · 2022: $1,201 · 2023: $599 · 2024: $1,399 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,052.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $662.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $622.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $548.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $515.33 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $502.69 | 2020-2025 | Vraylar |
| Boston Scientific Corporation | $374.20 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $362.01 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $346.25 | 2019-2025 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $193.65 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.03 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $161.85 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $159.51 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.89 | 2022 | |
| Allergan, INC. | $126.19 | 2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.